Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.
You can change your choice at any time.
Tag
Clonal hematopoiesis of indeterminate potential (CHIP) poses a novel cardiovascular risk. This article explores challenges and strategies for designing cardiovascular outcomes trials tailored to CHIP’s genetic heterogeneity and clinical com
Longitudinal analysis of 371 aplastic anemia patients reveals distinct patterns of clonal hematopoiesis under immunosuppressive therapy, highlighting variable mutation dynamics, cytogenetic changes, and progression risks.
Germline and somatic variants in DNMT3A and other CHIP genes elevate pulmonary arterial hypertension risk, including connective tissue disease-associated forms, through pro-inflammatory pathways, highlighting novel biomarkers and therapeuti
Clonal hematopoiesis (CHIP) significantly associates with increased silent brain lesions and progressive cognitive decline in atrial fibrillation patients, highlighting a novel neurovascular risk factor with implications for patient managem
This review synthesizes evidence linking periodontitis-induced inflammation with clonal hematopoiesis, exploring implications for tumor metastasis, trial methodology, and microbiome-host crosstalk.
This cohort study reveals that clonal hematopoiesis of indeterminate potential (CHIP) independently increases age-related macular degeneration (AMD) risk, with amplified effects when combined with high genetic susceptibility, especially in
A large whole-genome sequencing study found tumor-infiltrating clonal hematopoiesis in 18.4% of solid tumors, linked to older age, prior cytotoxic chemotherapy, and worse overall survival, with particularly strong associations in breast can
A substudy of the LoDoCo2 trial suggests that low-dose colchicine may attenuate the expansion of specific clonal hematopoiesis driver mutations, particularly TET2, offering a potential mechanism for reducing cardiovascular risk by slowing t
Data from the REPRIEVE trial indicates that while general clonal hematopoiesis is common in people with HIV, only large clones (VAF ≥10%) significantly elevate the risk for myocardial infarction and revascularization, independent of traditi
A UK Biobank whole‑genome study finds polygenic, rare monogenic, and somatic (CHIP) variants each independently associate with incident atrial fibrillation (AF); combined genomic profiling plus clinical risk (CHARGE‑AF) improves discriminat
This study reveals that clonal hematopoiesis of indeterminate potential (CHIP) in adults aged 70+ does not increase cardiovascular risk but is associated with heightened bleeding risk. Aspirin showed no additional benefits or harms for thos
A secondary analysis of the ASPREE trial reveals low-dose aspirin’s heterogeneous effects on cancer prevention in older adults, highlighting clonal hematopoiesis of indeterminate potential (CHIP) as a key predictor for benefit.
Clonal hematopoiesis of indeterminate potential (CHIP) is linked to a significantly increased risk of new-onset myocarditis and pericarditis, especially involving DNMT3A and TET2 mutations, highlighting a potential target for preventing inf
Clonal hematopoiesis (CH) occurs frequently in patients receiving CD19 or BCMA CAR T therapy and correlates with a higher risk of severe cytokine release syndrome (CRS), suggesting CH as a potential biomarker for CRS risk and a target for p